Pharma Equity Group A/S Cl A (CO:PEG) — Market Cap & Net Worth
Market Cap & Net Worth: Pharma Equity Group A/S Cl A (PEG)
Pharma Equity Group A/S Cl A (CO:PEG) has a market capitalization of $16.71 Million (Dkr106.80 Million) as of July 21, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #25657 globally and #116 in its home market, demonstrating a 10.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharma Equity Group A/S Cl A's stock price Dkr0.09 by its total outstanding shares 1227541937 (1.23 Billion). See PEG capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Pharma Equity Group A/S Cl A Market Cap History: 2015 to 2026
Pharma Equity Group A/S Cl A's market capitalization history from 2015 to 2026. Data shows change from $398.79 Million to $16.71 Million (-27.61% CAGR).
Pharma Equity Group A/S Cl A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharma Equity Group A/S Cl A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
285.74x
Pharma Equity Group A/S Cl A's market cap is 285.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $301.17 Million | $1.05 Million | -$1.03 Million | 285.74x | N/A |
Competitor Companies of PEG by Market Capitalization
Companies near Pharma Equity Group A/S Cl A in the global market cap rankings as of July 21, 2026.
Key companies related to Pharma Equity Group A/S Cl A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
Pharma Equity Group A/S Cl A Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharma Equity Group A/S Cl A's market cap moved from $398.79 Million to $ 16.71 Million, with a yearly change of -27.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr16.71 Million | -6.85% |
| 2025 | Dkr17.94 Million | -50.84% |
| 2024 | Dkr36.49 Million | -55.81% |
| 2023 | Dkr82.58 Million | -6.01% |
| 2022 | Dkr87.87 Million | -18.30% |
| 2021 | Dkr107.55 Million | -40.58% |
| 2020 | Dkr181.01 Million | -48.50% |
| 2019 | Dkr351.47 Million | +49.28% |
| 2018 | Dkr235.44 Million | -26.20% |
| 2017 | Dkr319.03 Million | +5.93% |
| 2016 | Dkr301.17 Million | -24.48% |
| 2015 | Dkr398.79 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of Pharma Equity Group A/S Cl A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.71 Million USD |
| MoneyControl | $16.71 Million USD |
| MarketWatch | $16.71 Million USD |
| marketcap.company | $16.71 Million USD |
| Reuters | $16.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more